http://www.udel.edu/OHS/bbpdecline.pdf
I may be at risk of acquiring hepatitis B virus (HBV) infection.
I have been given the opportunity to be vaccinated with hepatitis B vaccine, at no charge to myself.
However, I decline hepatitis B vaccination at this time.
I understand that by declining this vaccine, I continue to be at risk of acquiring hepatitis B, a serious disease.
If in the future I continue to have occupational exposure to blood or other potentially infectious materials and I want to be vaccinated with hepatitis B vaccine, I can receive the vaccination series at no charge to me.
Please attach a copy of any vaccination verification if possible.

reshep

While our knowledge of effective interventions aimed at preventing transmission of hepatitis C and minimising the impact of HCV infection is improving, much more is still needed.
Transmission in relation to tattooing, skin-piercing, medical and dental procedures, and ual and vertical transmission are all important areas of investigation, but as current information suggests they are responsible for very small proportions of the total burden of infections they are not recommended to be priorities for research.
With the rare exception of extrahepatic disease (e.g. non-Hodgkin's lymphoma, essential cryoglobulinemia), the only causes of death from chronic HCV infection are liver failure, haemorrhage from complications of portal hypertension and hepatocellular carcinoma (HCC).

"On page 8 of the RFA, it states: 'Applicants may design projects that address one or both funding priorities, but each project must stand on its own merit.'
"We assume that between the efforts of the V.A. and local efforts, the 50% mandate of serving veterans will be met.
"It is not clear what kind of counseling services the RFA would like to see provided.
Counseling may also include information about community resources available for HCV infected patients for medical evaluation and social support, as appropriate.
Can additional letters be added if they support the case for the applicant agency to carry out the project?
Proposed budgets must contain indirect costs at a rate no greater than 15% of the total personnel costs including benefits.

hepatitis_b

Hepatitis B is a serious disease caused by a virus that attacks the liver.
Each year in the United States, more than 200,000 people of all ages get hepatitis B and close to 5,000 die of sickness caused by HBV.
Sometimes, people who are infected with HBV never recover fully from the infection; they carry the virus and can infect others for the rest of their lives.
How great is your risk for hepatitis B?
If you are at risk for HBV infection, ask your health-care provider about hepatitis B vaccine.
Vaccine for hepatitis B is recommended for people of all ages.

hepatitis report

There are two phases of symptoms, (a) the prodromal illness which are flu-like symptoms (malaise, myalgia, fatigue) often with right abdominal pain; and (b) the icteric illness which is jaundice.
If chronic infection occurs there are often only physicial signs after many years of infection.
Questionnaires were sent to Lead Clinicians in 27 Genitourinary Medicine Clinics within North Thames Region.
Over half (60%) of the units routinely offer vaccination to HIV-positive patients immediately following a negative Hepatitis B result; 33% only offer this dependant upon risk factors; one unit does not offer vaccination at all.
A similar % of patients were diagnosed with Hepatitis B or C infection prior to HIV-positive diagnosis -- 32% diagnosed with Hepatitis B and 35% with Hepatitis C.

hep_c_june_2001

HAV is the most common cause of acute infection, followed by HBV and HCV; however, HCV is the most likely to result in chronic infection.
As with many viral infections, chronic infection with HCV is difficult to eradicate and, until recently, treatments for chronic HCV infection had very low response rates---more than half of all patients failed to respond to treatment.
IFN monotherapy for HCV infection was first introduced over 10 years ago, and the currently available IFNs have similar efficacy and safety profiles.
While pegylated IFN monotherapy is significantly more effective than standard IFN monotherapy, it is not as effective as combination therapy with IFN plus RBV.
Results from these combination trials have been positive, and were described by Dr. Rossi as "the next big step" for the treatment of HCV.

hepp2000-06

http://www.aegis.com/files/hepp/hepp2000-06.pdf
For the treatment of HIV infection, many physicians opt to use combination antiretroviral therapy which is not addressed by the FDA.
The hepatitis C virus (HCV) is responsible for 60-70% of chronic hepatitis and 30% of cirrhosis, end stage liver disease, and liver cancer in the United States.
Because of the high cost of treatment, time spent preparing patients and supporting them while on treatment is likely to be cost effective.* Other interventions that are thought to be helpful for the management of HCV include hepatitis A (HAV) vaccination (8).
Analyses of the effect of HCV and HIV coinfection on progression of either disease are often confounded by concurrent risk factors for progression.

regInfo29

This WorkCover Corporation information sheet has been developed in consultation with Workplace Services and is provided to offer guidance on a particular aspect of legislation.
This information sheet is designed to pro v i d e e m p l o y e rs and employees with information about hepatitis A in the workplace.
The infection spreads when the virus is taken in by mouth into the digestive tract of another person.
What occupational groups are at risk of hepatitis A infection?
Employees do not have to disclose the nature of their infection to their employer unless they are working in occupations where they could potentially infect others.

http://www.ci.austin.tx.us/health/tableofcontents.pdf
Is there a vaccine or other drug to help prevent hepatitis C infection?
What resources are available for clinicians who care for patients with hepatitis C?
Are health care workers at increased risk for getting hepatitis C?
What should be done if a health care worker is exposed to HCV positive blood such as a needlestick?
What should people do if they have hepatitis C or think they are at risk?
What are the drug treatment resources in our community?
What can be done about the side effects of interferon or ribavirin?
Can children be given interferon therapy for chronic hepatitis C?

JCM_1996_v34_p2552-2558

http://hpgl.stanford.edu/publications/JCM_1996_v34_p2552-2558.pdf
At least 70% of infected patients develop chronic infection, andapproximately20%progresstocirrhosis(44).Onthebasis of sequence comparisons, HCV has been classified under a separategenusintheFlaviviridaefamily,themembersofwhich arepositive-strandedRNAvirusesthatencodeviralproteinsin a single, long open reading frame (32).
In order to compare the sensitivity of the 3 9NCR PCRtothoseofotherassays,theseeightserumsampleswereseriallydilutedin normal HCV-negative serum and then tested by the 3 9NCR assay.
HCV is generally present in serum at levels (less than 10 eq/ml) (18, 20) lower than that of hepatitis B virus (approximately 109 eq/ml) (15).
After the initial round of RT and PCR, additional amplification of the HCV nucleic acid signal by hybridization or nested PCR is usually required (19).

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 |